Your browser doesn't support javascript.
loading
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard, Nicolas; Bar, Jair; Garrido, Pilar; Garassino, Marina C; McDonald, Fiona; Mornex, Françoise; Filippi, Andrea R; Smit, Hans J M; Peters, Solange; Field, John K; Christoph, Daniel C; Sibille, Anne; Fietkau, Rainer; Haakensen, Vilde D; Chouaid, Christos; Markman, Ben; Hiltermann, T Jeroen N; Taus, Alvaro; Sawyer, William; Allen, Allison; Chander, Pratibha; Licour, Muriel; Solomon, Benjamin.
Afiliação
  • Girard N; Institut du Thorax Curie Montsouris, Institut Curie, Paris, France and UVSQ, Paris Saclay, Versailles, France. Electronic address: nicolas.girard2@curie.fr.
  • Bar J; Institute of Oncology, Sheba Medical Centre, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Garrido P; Medical Oncology Department, Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, Spain.
  • Garassino MC; Department of Hematology/Oncology, The University of Chicago, Chicago, Illinois.
  • McDonald F; Lung Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Mornex F; Department of Radiation Oncology, Centre Hospitalier Universitaire de Lyon, Lyon, France.
  • Filippi AR; Radiation Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy.
  • Smit HJM; Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands.
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Field JK; Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Christoph DC; Department of Medical Oncology/Hematology, Evang. Kliniken Essen-Mitte, Evang. Huyssens-Stiftung Essen-Huttrop, Essen, Germany.
  • Sibille A; Department of Pneumology and Allergology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
  • Fietkau R; Department of Radiation Oncology, Universitätsklinikums Erlangen, Erlangen, Germany.
  • Haakensen VD; Department of Oncology and Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Chouaid C; Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
  • Markman B; Cabrini Hospital and Monash University, Melbourne, Victoria, Australia.
  • Hiltermann TJN; University of Groningen, Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands.
  • Taus A; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.
  • Sawyer W; AstraZeneca, Cambridge, United Kingdom.
  • Allen A; AstraZeneca, Gaithersburg, Maryland.
  • Chander P; AstraZeneca, Gaithersburg, Maryland.
  • Licour M; AstraZeneca, Courbevoie, France.
  • Solomon B; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia.
J Thorac Oncol ; 18(2): 181-193, 2023 02.
Article em En | MEDLINE | ID: mdl-36307040

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos